title: Erlotinib might be a double-edged sword in HCC.
authors.affiliation: Department of Infection and Liver Diseases, Liver Research Center, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, P.R. China.
authors.forename: Jin-Zhong
authors.initials: JZ
authors.lastname: Dong
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Wang
authors.forename: Sai-Nan
authors.initials: SN
authors.lastname: Zhang
authors.forename: Zhuo-Lin
authors.initials: ZL
authors.lastname: Zou
authors.forename: Ming-Qin
authors.initials: MQ
authors.lastname: Lu
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control*; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008103:Liver Cirrhosis / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000517:prevention & control*; D008297:Male; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D066246:ErbB Receptors